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Abstract
Background: Alzheimer’s disease (AD) is the most prevalent form of age-related dementia, and its effect on society
increases exponentially as the population ages. Accumulating evidence suggests that neuroinflammation, mediated
by the brain’s innate immune system, contributes to AD neuropathology and exacerbates the course of the disease.
However, there is no experimental evidence for a causal link between systemic inflammation or neuroinflammation
and the onset of the disease.
Methods: The viral mimic, polyriboinosinic-polyribocytidilic acid (PolyI:C) was used to stimulate the immune system
of experimental animals. Wild-type (WT) and transgenic mice were exposed to this cytokine inducer prenatally
(gestation day (GD)17) and/or in adulthood. Behavioral, immunological, immunohistochemical, and biochemical
analyses of AD-associated neuropathologic changes were performed during aging.
Results: We found that a systemic immune challenge during late gestation predisposes WT mice to develop
AD-like neuropathology during the course of aging. They display chronic elevation of inflammatory cytokines, an
increase in the levels of hippocampal amyloid precursor protein (APP) and its proteolytic fragments, altered Tau
phosphorylation, and mis-sorting to somatodendritic compartments, and significant impairments in working
memory in old age. If this prenatal infection is followed by a second immune challenge in adulthood, the
phenotype is strongly exacerbated, and mimics AD-like neuropathologic changes. These include deposition of APP
and its proteolytic fragments, along with Tau aggregation, microglia activation and reactive gliosis. Whereas Aβ
peptides were not significantly enriched in extracellular deposits of double immune-challenged WT mice at
15 months, they dramatically increased in age-matched immune-challenged transgenic AD mice, precisely around
the inflammation-induced accumulations of APP and its proteolytic fragments, in striking similarity to the post-
mortem findings in human patients with AD.
Conclusion: Chronic inflammatory conditions induce age-associated development of an AD-like phenotype in WT
mice, including the induction of APP accumulations, which represent a seed for deposition of aggregation-prone
peptides. The PolyI:C mouse model therefore provides a unique tool to investigate the molecular mechanisms
underlying the earliest pathophysiological changes preceding fibrillary Aβ plaque deposition and neurofibrillary
tangle formations in a physiological context of aging. Based on the similarity between the changes in immune-
challenged mice and the development of AD in humans, we suggest that systemic infections represent a major risk
factor for the development of AD.
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Background
Neuroinflammation was one of the prominent patho-
logical features described by Alois Alzheimer in his first
case report in 1907. Today we know that specific mar-
kers of neuroinflammation are selectively enriched in
brain areas affected by Alzheimer’s disease (AD) neuro-
pathology [1], and that individuals with high plaque bur-
den without dementia show virtually no evidence of
neuroinflammation [2]. This is further supported by
positron emission tomography (PET) imaging studies,
which have shown that cognitive status is inversely cor-
related with microglial activation in patients with AD
[3]. In addition, recent genome-wide association studies
have identified significant correlations between compo-
nents of the innate immune system and the incidence of
sporadic AD [4], supporting the link between the im-
mune system and AD pathophysiology suggested by pre-
vious retrospective epidemiological studies in humans
[5,6].
However, the precise role of neuroinflammation in the
disease etiology is still controversial, ranging from repre-
senting a possible cause to being a by-product of the dis-
ease [7] or even being beneficial [8]. In 1996 it was
proposed that interleukin (IL)-1, an inflammatory cyto-
kine whose levels are increased in the brains of patients
with AD [9], may represent a driving force in the patho-
genesis of AD [10,11]. Although this hypothesis was in
accordance with a meta-analysis of 17 epidemiological
studies indicating that non-steroidal anti-inflammatory
drugs might decrease the risk of developing AD [12],
subsequent randomized trials not only failed to show a
beneficial effect of anti-inflammatory drugs on the eti-
ology of AD [13,14], but in fact found an increase in AD
incidence in patients with mild cognitive impairment
treated with these drugs as compared to placebo [15].
The resolution of apparent inconsistency came only re-
cently with the revision of the Alzheimer`s Disease Anti-
inflammatory Prevention Trial (ADAPT) hypothesis that
supports a beneficial role of anti-inflammatory drugs
only in the early, asymptomatic, phases of the disease
[16]. However, in vivo experimental evidence to support
an early and potentially causative role for systemic infec-
tions and neuroinflammation in the etiology of sporadic
AD is still missing.
To elucidate the early role of inflammatory processes
in the development of AD-like pathology in mice, we
used the viral mimic polyriboinosinic-polyribocytidilic
acid (PolyI:C), a synthetic analog of double-stranded
RNA, to stimulate the immune system of our experi-
mental animals [17,18]. We have previously shown that
a single exposure to PolyI:C during late gestation trig-
gers the expression of several inflammatory cytokines in
the fetal brain [19], evokes a reduction in adult neurogen-
esis, accompanied by memory impairments [19,20], and
accelerates protein depositions in the hippocampus of
the adult offspring [21]. In the current study, we tested
the hypothesis that the prenatal immune challenge dur-
ing late gestation results in pathological aging, and pre-
disposes the offspring to aging-associated AD-like
neuropathology and cognitive decline [22]. In addition,
we tested the effects of systemic immune challenge in
adulthood on the progression of the AD-like phenotype
either in prenatally challenged wild-type (WT) mice or
in transgenic AD (3xTg-AD) mice [23].
Methods
Animals
All experimental procedures were approved by the local
authorities of the Cantonal Veterinary Office in Zurich
and carried out in agreement with the Principles of La-
boratory Animal Care (National Institutes of Health
publication number 86–23, revised 1985).
Animals (see Table 1 for a complete list) were housed
in groups of three to four in an optimized in-house
hygiene area (University of Zurich Irchel, Zurich, Switz-
erland) or standard housing conditions in the Laboratory
of Behavioural Neurobiology (ETH Zurich, Schwerzen-
bach, Switzerland) under a 12 hour light/dark cycle, with
access to food and water ad libitum. Transgenic (3xTg-AD;
encoding APPswe, and TauP301L on a homozygous
PS1M146V knock-in background [23]) and the non-
transgenic mice with the same genetic background (129/
C57Bl6) were obtained from Dr Frank LaFerla, University
of California, Irvine, CA, USA. WT C57BL/6 J mice were
obtained from the breeding facility of the Institute of La-
boratory Animal Science, University of Zurich (LTK
Fuellinsdorf).
Polyriboinosinic-polyribocytidilic acid injections
Pregnant mouse dams of the C57Bl/6 J strain were given
a single intravenous injection of 5 mg/kg PolyI:C potas-
sium salt (P9582, 50 mg; Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) dissolved in 0.9% saline (NaCl) with
an injection volume of 5 ml/kg body weight or an
equivalent volume of saline at gestation day (GD) 17.
The animals were mildly restrained during the injection
procedure using an acrylic mouse restrainer, and after
the injection, were immediately placed back in their
home cage and left undisturbed until the first cage
change at 1 week after delivery.
Behavioral testing
To assess a putative cognitive decline in aged mice
exposed to a prenatal immune challenge, adult
(5 months) and aged (20 months) mice were tested in
the elevated Y-maze spontaneous alternation task
(Table 1). This task is used to measure spatial recogni-
tion memory that depends on proper hippocampal
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functions, as confirmed by the severe memory impair-
ment after excitotoxic lesion of this brain region [24]. It
is based on the innate tendency of rodents to explore
novel environments, that is, their preference to investi-
gate a new arm of the maze rather than returning to one
that was previously visited. This paradigm avoids the
effects of other methods such as punishment (such as
electric shock) or reward (such as food following phases
of deprivation) that are commonly used in other para-
digms and may have non-specific effects on the results.
In addition, it does not require learning of a rule, thus it
is useful for studying performance in rodents, particu-
larly in aged animals.
Apparatus
The Y-maze apparatus was made of transparent Plexiglas
and consisted of three identical arms (500 mm long×90 mm
wide) surrounded by transparent Plexiglas walls 100 mm in
height. The three arms radiated from a central triangle
(80 mm on each side) and were spaced 120 degrees
from each other. The floor of the maze was covered
with sawdust bedding, which was changed between
each test run. The maze was elevated 900 mm above
the floor, and was positioned in a well-lit room
enriched with distal spatial cues. A digital camera was
mounted above the Y-maze apparatus. Images were cap-
tured at a rate of 5 Hz, and transmitted to a PC running
the EthoVision tracking system (Noldus Information
Technology), which calculated the total distance moved
and the number of entries into the three arms and the
center zone of the Y-maze.
Procedure
Mice were placed in the center of the Y maze. An obser-
ver in an adjacent room viewed the mice through a video
camera, and recorded the number and sequence of arm
entries (defined as entry of the whole body into an arm)
during a period of 5 minutes. Alternation was defined as
entry into the three arms in any non-repeating order
(for example, ABC, BAC, CBA). The percentage alterna-
tion was calculated as the total number of alternations
divided by the possible alternations given the number of
arm entries (total number of arm entries, 2). In addition
to the analysis of percentage alternation, the total dis-
tance moved and the total number of arm entries were
recorded and analyzed to assess general activity during
the 5-minute test period.
Mouse brain-tissue preparation
The tissue was fixed by perfusion and processed as
described previously [21]. Briefly, animals were deeply
anesthetized by intraperitoneal injection of pentobarbital
(4 ml/kg body weight; Nembutal™; Lundbeck Inc.,
Deerfield, IL, USA) and perfused transcardially with PBS
Table 1 Overview of the experimental animals used in this study
Strain Genotype Animals, n Treatment Time of tissue
collection (use)
Experiment
Prenatal Adult
129/C57Bl/6 Non-Tg 4 NaCI, 4 PolyI:C – 4 months 15 months (IHC) Systemic infection in TgAD mice
3xTg-AD 5 NaCI, 7 PolyI:C – 4 months 15 months (IHC)
C57Bl6/J Non-Tg 5 NaCI, 5 PolyI:C GD17 – 3 weeks (E) Prenatal infection in non-Tg mice:
longitudinal changes in cytokine and
brain APP/pTau levels and cognitive
performance
4 NaCI, 4 PolyI:C GD17 – 3 months (IB/E)
5 NaCI, 5 PolyI:C GD17 – 5 months (E)
16 NaCI, 15 PolyI:C GD17 – 5 months (BT)
4 NaCI, 4 PolyI:C GD17 – 6 months (IB/E)
6 NaCI, 6 PolyI:C GD17 N* 12 months (IB)
4 NaCI, 5 PolyI:C GD17 – 15 months (IB/E)
6 NaCI, 6 PolyI:C GD17 – 15 months (IHC)
18 NaCI, 13 PolyI:C GD17 – 20 months (BT)
C57Bl6/J Non-Tg 6 NN*, 6 NP,
6N*, 7 PP
GD17 9 months 12 months (IB) Prenatal and adult infection in non-Tg
mice
10 NP, 11 PP GD17 12 months 15 months (IHC)
6 NN, 5 NP, 4 PN,
5 PP
GD17 15 months 18 months (IHC)
Abbreviations: APP, amyloid precursor protein; BT, behavioral testing; E, ELISA; GD, gestational day; IB, immunoblotting; IHC, immunohistochemistry; N =NaCI
(0.9% saline); NN, prenatal and adult NaCI treatment; NP, prenatal NaCI and adult PolyI:C treatment; PN, prenatal PolyI:C and adult NaCI treatment; PP, prenatal
and adult PolyI:C treatment; pTau, phosphorylated Tau.
*Control group of first cohort used in experiment 3.
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(pH 7.4), followed by 4% paraformaldehyde in PBS
(Sigma-Aldrich). The brains were post-fixed for 4 hours at
4°C followed by cryoprotection for 24 hours in 30% su-
crose. Randomly sampled serial sections (cut at 40 μm)
were collected throughout the hippocampal formation
starting at bregma level −0.82 to −3.64 [25], and stored at
−20°C in cryoprotectant solution (50 mmol/l sodium
phosphate buffer, pH 7.4, containing 15% glucose and 30%
ethylene glycol; Sigma-Aldrich) until immunohistochem-
ical or histological evaluation.
Immunohistochemistry
All the free-floating sections were treated for 10 minutes
with pepsin (Cat-No S3002; Dako, Carpinteria, CA,
USA) 0.15 mg/ml in 0.2 N HCl at 37°C, to unmask epi-
topes and reduce non-specific staining [26,27]. Sections
were briefly washed with PBS (pH 7.4). The pepsin-
treated brain sections were then incubated overnight at
4°C in the primary antibody solutions diluted in PBS
(see Table 2 for details) containing 2% normal goat
serum and 0.2% Triton X-100.
After three washes in PBS, tissue sections processed
for immunoperoxidase labeling were incubated for 30
minutes at room temperature in biotinylated secondary
antibodies (diluted 1:500; Jackson ImmunoResearch La-
boratories Inc. West Grove, PA, USA), followed by three
rinses in PBS. A commercial kit (Vectastain Kit; Vector
Laboratories; Burlingame, CA, USA) was then used with
3,3-diaminobenzidine (DAB; Sigma–Aldrich Inc.), and
sections were stained for 5 to 10 minutes [21]. After
three washes in PBS, sections were mounted onto gelati-
nized glass slides and air-dried overnight. The sections
were then dehydrated through ethanol, cleared in xylene,
mounted with resinous mounting medium (EukittTM
Sigma-Alrich), and coverslipped.
For immunofluorescence staining, sections were incu-
bated for 30 minutes at room temperature with secondary
antibodies coupled to Alexa488 (diluted 1:1000; Molecular
Probes, Eugene, OR, USA), Cy3 (diluted 1:500; Molecular
Probes) or Cy5 (diluted 1:200; Jackson ImmunoResearch
Laboratories).
For the visualization of β-sheet enriched proteinous
aggregates, sections were counterstained with thioflavinS
(Sigma-Aldrich), involving incubation for 10 minutes in
filtered 0.1% aqueous thioflavinS solution at room
temperature, followed by two washes for 5 minutes each
in 80% EtOH, one wash for 5 minutes in 95% ethanol,
and three washes for 5 minutes each in distilled water.
Brain sections were air-dried in the dark and mounted
with aqueous permanent mounting medium (Dako) con-
taining 1.5 μg/ml DAPI (Thermo Scientific (Schweiz)
AG, Reinach, Switzerland).
Double-or triple-labeling was visualized by confocal
microscopy (LSM-710; Zeiss, Jena, Germany) using 40×
(numerical aperture (NA) 1.3) and 63× (NA 1.4)
objectives and sequential acquisition of separate chan-
nels. Z-stacks of consecutive optical sections (6 to 12;
1024 × 1024 pixels, spaced 0.5 to 1 μm in z) were
summed and projected in the z dimension (maximal in-
tensity), and merged using the image analysis software
Imaris (Bitplane, Zurich, Switzerland) for visual display.
Cropping of images, adjustments of brightness and con-
trast were performed using Adobe Photoshop and were
identical for each staining.
Fluoro-Jade and silver staining
For the detection of dystrophic neurites and proteinous
aggregates in immune-challenged 3xTg-AD mice, we
used two commercial kits (Fluoro-JadeW Kit (Millipore,
Billerica, MA, USA, catalog number AG325) and FD
Table 2 Summary of antibodies used in this study
Antibody Manufacturer Description/Nr Dilution Application
β-Actin Millipore, Billerica, MA, USA Mouse monoclonal, clone 4, MAB1522 1:20,000 IB
Amyloid-β1–16 Covance, Princeton, NJ, USA Mouse monoclonal, clone 6E10, SIG-39320 1:1,000 IHC/IB
Amyloid-β1–40/42 Millipore Rabbit polyclonal, AB5076 1:2,000 IHC
APP (A4), N-term Millipore Mouse monoclonal, clone 22 C11, MAB348 1:2,000 IHC/IB
APP, C-term Sigma-Aldrich Chemie GmbH, Buchs, CH Rabbit polyclonal, A8717 1:4,000 IB
Cleaved Caspase-6 Cell Signaling Technology, USA Rabbit polyclonal, Nr. 9751 1:500 IHC
CD68 AbD Serotec Ltd, Oxford, UK Rat monoclonal, MCA341R 1:2,000 IHC
GFAP Dako Schweiz AG, Baar, CH Rabbit polyclonal, Z334 1:5,000 IHC
pTauT205 Abcam, Cambridge, UK Rabbit polyclonal, ab4841 1:1,000 IHC/IB
PHF-Tau Thermo Fisher Scientific, Fremont, CA, USA Mouse monoclonal, MN1060 1:1,000 IB
Tau-Ab2 Thermo Fisher Scientific Mouse monoclonal, total Tau, clone Tau-5 1:4,000 IB
APP, amyloid precursor protein; GFAP, glial fibrillary acidic protein; IB, immunoblotting; IHC, immunohistochemistry; pTau, phosphorylated Tau; PHF, paired helical
filament.
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NeuroSilverTM Kit II (FD NeuroTechnologies Inc, Elli-
cott City, MD, USA).
For the Fluoro-Jade staining, tissue sections processed
for anti-Aβ immunofluorescence staining were mounted
on gelatin-coated slides and air-dried for 2 to 3 hours,
then stained in accordance with the manufacturer’s
protocol. In brief, slides were immersed in a solution of
1% sodium hydroxide in 80% ethanol for 5 minutes.
Next, they were washed in 70% ethanol and distilled
water for 2 minutes each. This was followed by 10 min-
utes incubation in a solution of 0.06% potassium per-
manganate. After rinsing the slides in distilled water,
they were incubated in the staining solution for 20 min-
utes (dye concentration: 0.0004%). The slides were
washed three times in distilled water before air-drying
for 1 hour. After immersion in xylene, slides were cover-
slipped with aqueous mounting medium containing
DAPI (Dako, Glostrup, Denmark.
For the silver staining, free-floating perfusion-fixed
brain slices (40 μm thick) prepared for normal immuno-
histochemistry, were processed in accordance with the
manufacturer’s instructions. For both procedures, con-
trol sections obtained from adult WT mice that had
received unilateral intra-hippocampal injections of kainic
acid (a manipulation that results in rapid degeneration
of hippocampal interneurons and CA1 pyramidal cells
[28]) served as controls.
Quantification of immunohistochemical staining
All immunoperoxidase-stained slides were scanned with
an automated upright slide-scanning microscope (Mirax
Midi Slide Scanner; Zeiss) in bright-field mode. Images
were acquired with a digital camera (1288 × 1040 pixels,
with a pixel size of 0.23 μm; AxioCam monochrome
charge-coupled display; Zeiss) with a 20× objective (NA
0.8) using the software Pannoramic Viewer (version 1.8.3;
3D Histech Ltd, Budapest, Hungary). A densitometric seg-
mentation analysis was performed for the anti-Aβ
(15 months, prenatal infection time course), anti-
phosphorylated (p)Tau (hilar mossy cells, 15 months, pre-
natal infection), anti-glial fibrillary acidic protein (GFAP)
(astrocytes, double immune-challenge experiment), and
anti-CD68 (activated microglia, double immune-challenge
experiment) immunoperoxidase stains to measure the
relative percentage and the mean size of the labeled cells
covered by the immunoreactive signals in the hippocam-
pal formation. Here, the immunoreactivity (IR) in the
neuropil served as the reference for non-specific back-
ground staining.
The quantitative analyses were performed on one ran-
domly selected hemisphere and the researcher was
blinded to the genotype/treatment of the animals.
Hippocampi from four to six brain sections per animal
were outlined, and the positively labeled cells identified
by using a segmentation threshold with Histoquant soft-
ware (3D Histech Ltd, Budapest, Hungary). The overall
area and mean size of all segmented cells were calcu-
lated and divided by the total area of the outlined region.
For the anti-APP and pTau IR in axonal and dendritic
regions (experiments involving mice exposed to a prenatal
infection and a double immune-challenge), a similar pro-
cedure was applied using the standard threshold algorithm
of ImageJ software (version 1.45b; NIH, Bethesda, MD,
USA) applied to exported high-magnification TIFF images
(40x) from the digital Pannoramic Viewer. Pixel brightness
was measured in several disease-relevant hippocampal sub-
regions, including CA1 stratum pyramidale, radiatum, lacu-
nosum moleculare, dentate gyrus (DG) inner and outer
molecular layer, neuropil in the hilus, CA3 stratum pyrami-
dale, and lucidum, and in the corpus callosum (serving for
background correction). For the double immune-
challenged mice and their controls, one series of randomly
sampled brain sections (n=6, sampling fraction 1/12) pro-
cessed for anti-Aβ1–40/42 immunohistochemistry was used
to stereologically estimate the numerical density of Aβ
deposits in the hippocampus proper, the lateral entorhinal
cortex, and neocortical areas (somatosensory cortex). The
volumes were estimated by the formula
V ¼
X
A tnom  1=ssf
where
P
A= the summed area of the brain region, tnom=
the nominal section thickness, and ssf= the section sam-
pling fraction. Aβ plaques, identified by their fibrillary
morphology, were counted exhaustively within the corre-
sponding areas, using the marker counting tool of Histo-
quant software. The total number of plaques (Ptot) and the
numerical density (Ptot/mm3) were estimated by the formula
Ptot=mm3 ¼
X
P  1=ssf mm3
where
P
P is the sum of plaques. Densitometric and stereo-
logical values were averaged per animals and used in the
statistical analyses.
Processing of human post-mortem tissue
Paraffin wax-embedded brain sections (4 μm thick) of
the temporal lobe obtained from a 88-year-old patient
diagnosed with AD (generously provided by Professor
Dr Manuela Neumann, Institute of Neuropathology,
University of Zurich, Zurich, Switzerland) were dewaxed
in xylene (3 × 3 minutes) and rehydrated in decreasing
concentrations of ethanol (2 × 100%, 96%, 70% ethanol,
and 2 ×H2O for 3 minutes each) followed by washing for
5 minutes in 50 mmol/l Tris-buffered saline (pH 7.4). Op-
timal antigen retrieval was achieved by treating sections
for 5 minutes with 95% formic acid (involving the anti-
amyloid-β1–40/42 antibody, 1:200, AB5076; Millipore) or a
citrate buffer (0.1 mol/l citric acid and 0.1 mol/l tri-
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sodium citrate-2-hydrate) and microwaving at 84°C fol-
lowed by treatment with pepsin (involving the anti-N-APP
antibody, 1:500, MAB348, clone 22C11; Millipore) as
described. Before the primary antibody incubation, sec-
tions were treated for 1 hour with blocking solution (PBS
(pH 7.4) containing 5% normal horse serum, 5% normal
goat serum and 4% BSA). Primary antibodies were diluted
in PBS (pH 7.4, with 2.5% normal horse serum, 2.5% nor-
mal goat serum and 2% BSA added), and sections were
then incubated with the primary antibody overnight in a
wet histochamber at 4°C under constant agitation. Sec-
tions were washed three times for 5 minutes each in PBS
(pH 7.4). Secondary antibodies coupled to either Alexa
Fluor 488 or Cy3 (diluted 1:1000 and 1:500, respectively,
in the same buffer as for primary antibodies; Molecular
Probes and Invitrogen, respectively) were added to the
sections and incubated for 45 minutes. To reduce auto-
fluorescence of intracellular lipofuscin in aged cells, we
adapted the protocol described previously [29]. Sections
were treated with 0.1% Sudan Black (Carl Roth GmbH,
Karlsruhe, Germany) in 70% methanol for 2 minutes in a
wet histochamber and briefly washed with PBS before
coverslipping. Sections were mounted with aqueous
mounting medium containing DAPI (Dako) to visualize
cell nuclei. Laser scanning confocal microscopy and digital
imaging was performed as described above for the murine
immunofluorescence staining.
Protein extracts and immunoblotting
Mice (Table 1) were decapitated, then the hippocampi
and cortices were immediately dissected and sonicated
on ice in 5 volumes of RIPA buffer (20 mmol/l Tris,
150 mmol/l saline, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS) containing protease (Mini Complete
TabletsTM; Roche, Diagnostics, Basel, Switzerland) and
phosphatase inhibitors (Sigma-Aldrich), and separated
by centrifugation at 40,000 g at 4°C for 20 minutes. The
pellet/membrane fraction was extracted in 20 μl of for-
mic acid and resuspended in 100 μl EBS buffer (50 mmol/
l Tris-Cl, pH 8.0, 120 mmol/l saline, 0.5% v/v Nonidet P-
40, 5 μg/ml leupeptin, 10 μg/ml aprotinin, 50 μg/ml
PMSF, 0.2 mmol/l sodium orthovanadate, 100 mmol/l so-
dium fluoride). Total protein concentrations of the pellet
and supernatant were measured with a spectrophotometer
(NanoDrop; Thermo Fisher Scientific Inc. Rockford, IL,
USA) or Bradford assay (BioRad laboratories Inc,
Hercules, CA, USA), respectively. Protein samples (20 μg)
were separated by SDS-PAGE using 10 to 20% Tris-
Tricine gels (Invitrogen, Carlsbad, CA, USA), blotted onto
0.1 μm nitrocellulose (Protran; Sigma-Aldrich) (see Table 3
for details). After blotting, the nitrocellulose membranes
were dried at room temperature for 20 minutes [30].
Membranes were blocked (Table 3) and incubated over-
night at 4°C with the primary antibodies (Table 2). Before
and after incubation with the secondary antibodies (horse-
radish peroxidase-conjugated antibodies; Jackson Immu-
noResearch Laboratories), membranes were washed for 1
hour in total (6 × 10 minutes) in Tris-buffered saline with
Triton X-100. The signal was visualized by the enhanced
chemiluminescence reaction (Amersham Biosciences Eur-
ope, Freiburg, Germany) in accordance with the manufac-
turer’s instructions. Quantitative analyses of the
immunoreactive bands were performed on digitalized
films using ImageJ software (NIH). Sum pixel brightness
values (the integrated density), corrected for non-specific
background and equal loading using β-Actin as a control,
were averaged per animal and included in the statistical
analysis.
ELISA
ELISA microtiter plates (catalog number EZBRAIN40/
42; Millipore) were used for the quantitative analysis of
Aβ1–40 and Aβ1–40/42. In addition, mouse-specific Aβ
and IL-1β ELISA microtiter plates (catalog numbers
KMB3481 and KMC0011, respectively; Invitrogen,
Camarillo, CA, USA) and a fluorokine multi analyte
profiling kit for the detection of IL-1α, IL-6, and
tumor necrosis factor α (TNFα; catalog number
LUM410; R & D Systems, Minneapolis, MN, USA) were
employed to confirm the murine origin of the selected
Table 3 Western blotting parameters
Antibody Run time, hours/voltage Transfer time hours Blocking reagent/time, hours Secondary antibody incubation, hours
total Tau/Ab-2 1.5 to 2/125 1.5 10% WBR1/1 1.5
PHF-Tau
pTauT205
APP, C-terminal 2/125 or 2.5/1003 1.5 10% FBS2/2 1
APP (A4) 3/1253 1.5 10% WBR/1 1.5
β-Actin4 10% WBR/1 1
FBS, fetal bovine serum (heat-inactivated); paired helical filament; WBR, Western blocking reagent (Roche Applied Science).
1Incubation of membrane in boiling PBS for 5 minutes recommended.
2Incubation of membrane in boiling PBS for 5 minutes required.
3Western blotting apparatus kept in the water bath at room temperature to prevent overheating.
4β-actin was measured for each blot after stripping (2% SDS at 56°C for 30 minutes).
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proteins. All assays were performed in accordance with
the manufacturer’s protocol. Samples (50 μl) of the
brain extracts (supernatant and pellet) or terminally col-
lected blood plasma samples were used and run in du-
plicate. After 30 minutes incubation in the substrate
solution (3,3′,5,5′-tetramethylbenzidine/peroxide mix-
ture), the reaction was stopped and the absorption
quantified using a microplate reader (Synergy HT
Multi-Mode; BioTek Instruments Inc, Winooski, VT,
USA) measuring the difference at 450 nm and 650 nm.
Statistical analyses
All analyses were performed with SPSS for Windows
(version 16; SPSS Schweiz AG, Zug, Switzerland).
ANOVA with ‘treatment’ as the main between-subjects
factor was performed for the behavioral test, the immu-
nohistochemical and immunoblotting analyses (anti-Aβ,
anti-pTau, anti-GFAP, anti-CD68 IR) involving double
immune-challenged mice (PP; PolyI:C at GD17 and in
adulthood), and their controls for NN (NaCl at GD17
and in adulthood), NP (NaCl at GD17, PolyI:C in adult-
hood), and PN (PolyI:C at GD17, NaCl in adulthood).
Significant main effects were explored further and the
corresponding mean values between groups were com-
pared using Fisher's least significant difference (LSD)
test. Planned comparisons (NaCl versus PolyI:C, NP ver-
sus PP) with Mann–Whitney U-tests were used for the
single and double immune-challenge experiments in-
volving immunohistochemical, immunoblotting, and
ELISA experiments assessing APP/Aβ and pTau levels.
Statistical significance was set at P<0.05.
Results
To elucidate the role of inflammatory processes in the
etiology of AD-like pathology in mice, we challenged
non-transgenic mouse dams with PolyI:C at GD17, and
analyzed the development and progression of AD-like
neuropathology in the offspring during adulthood and
aging. We first measured the inflammatory cytokine
IL-1β, which has been suggested to play a crucial role in
the etiology of AD [9-11]. We found that plasma IL-1β
levels were significantly increased in animals exposed
prenatally to PolyI:C versus saline (NaCl) subjects at the
time of weaning, and these levels remained higher
throughout aging both in plasma and brain tissue
(Figure 1A). In line with the finding that a long-term
peripheral infusion of IL-1β induces hippocampal cyto-
kine mRNA expression [31], we also found increased
levels of other cytokines, such as IL-1α and IL-6, in the
hippocampus of 15 month-old mice exposed to PolyI:C
compared with saline controls (Figure 1A; see Additional
file 1: Figure S1A-C). In addition, immunohistochemistry
using anti-CD68 antibodies, which predominantly la-
beled activated microglia/macrophages, identified the
presence of some microglia cells with altered morph-
ology in the hippocampus CA1 stratum lacunosum
moleculare (see Additional file 1: Figure S1D-K), indica-
tive of an activated state [32]. Furthermore, prenatal
PolyI:C exposure resulted in a significant age-dependent
increase in the amount of amyloid precursor protein
(APP) and its proteolytic fragments: α/β-secretase-gener-
ated ectodomains (soluble (s)APP), C-terminal fragments
(CTFs) and their γ-secretase-cleaved APP intracellular
domains (AICD), and β/γ-secretase-generated Aβ peptides
(Figure 1B-D; see Additional file 2: Figure S2A-C; see
Additional file 3: Figure S3A for schematic representa-
tion of APP and antibodies used to detect the proteo-
lytic fragments). Whereas the levels of APP, sAPP, and
CTFs were found to increase between 12 to 15 months
in PolyI:C compared with saline-treated subjects, the
levels of AICD, a neuroinflammation-inducing frag-
ment of APP [33], had already reached significantly
higher levels by 12 months (Figure 1D). Using densito-
metric analysis of APP IR, a significant increase in hip-
pocampal APP and its proteolytic fragments was also
found in 15 month-old PolyI:C-exposed versus saline-
treated mice (Figure 2A-C). Taken together, these
results suggest that a late-gestational immune chal-
lenge evokes a chronic neuroinflammatory state in
the offspring that is accompanied by a significant in-
crease in APP levels and amyloidogenic APP proces-
sing in the aged hippocampus.
Interestingly, levels of phosphorylated (p)TauT205 were
also significantly increased in PolyI:C mice relative to
controls at 6 and 15 months; however, they were signifi-
cantly reduced at 12 months of age without significant
changes in the levels of PHFs or total Tau (Figure 1E-F;
see Additional file 2: Figure S2D-F; see Additional file 3:
Figure S3B for schematic representation of Tau and the
antibodies used to detect the different phosphorylated
epitopes), suggesting dynamic and potentially compensa-
tory changes in the regulation of Tau phosphorylation.
Using an optimized antigen-retrieval protocol [26], we
were also able to identify, in 15-month-old PolyI:C-
treated animals, a striking mis-sorting of pTau from
axonal to somatodendritic compartments in hippocampal
neurons (Figure 2D-I), a suggested prerequisite for the
induction of synaptic dysfunction [34]. In line with
these observations, PolyI:C-treated mice showed a sig-
nificant aging-associated deficit in the Y-maze paradigm,
which was not attributable to putative differences in
sensory and locomotor activities (Figure 3). Thus, a
prenatal immune challenge is sufficient to trigger a
series of neuropathologic events that lead to a slow but
gradual increase in amyloidogenic APP processing, Tau
hyperphosphorylation and mislocalization, and cogni-
tive impairments, potentially representing a state of
increased vulnerability of the brain to AD.
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Based on these findings, we hypothesized that a sec-
ond systemic immune challenge in adulthood might ex-
acerbate the development of Aβ and Tau neuropathology
in non-transgenic mice. To test this, mice prenatally
exposed to PolyI:C (P) and their saline (N) controls were
challenged during aging (between 9 and 15 months) with
a second PolyI:C injection, or treated with saline, yielding
four treatment groups for comparison (NN, NP, PN, PP;
Table 1). Three months after the immune challenge, bio-
chemical and/or immunohistochemical analyses were per-
formed to examine the effect of the second exposure on
AD-like neuropathology. Having seen alterations in micro-
glial morphology/activity in the prenatally challenged co-
hort, we first analyzed potential changes in CD68.
Immunohistochemical analysis showed a significant in-
crease in CD68 IR in double immune-challenged mice
Figure 1 Prenatal immune challenge results in long-term alterations in interleukin (IL)-1β levels, amyloid precursor protein (APP)
processing, and Tau phosphorylation. (A) After prenatal exposure to polyriboinosinic-polyribocytidilic acid (PolyI:C), elevation of the
proinflammatory cytokines IL-1β in plasma and brain and IL-6 in brain was observed. (B,C) Quantification of APP and its proteolytic fragments in
hippocampal lysates of 15 month-old mice. Western blots (WB, left) and ELISA (right) using anti-N- and C-terminal APP, and Aβ1–40/1–42 specific
antibodies, respectively. WB values represent mean relative optical density normalized to β-actin and expressed in arbitrary units (AU). Lanes
represent different animals, and the inset highlights the size markers. (D) Overview of longitudinal APP-related biochemical changes (percentage
changes relative to saline (NaCl) occurring after prenatal viral-like infection. (E-F) WB, quantification (15 month-old mice), and longitudinal
changes in Tau phosphorylation in mice prenatally exposed to NaCl or PolyI:C, assessed using anti-paired helical filaments (PHFs), anti-pTauT205,
and anti-total Tau antibodies. Values represent mean± SEM, n = 4 to 7 mice per treatment and age. **P< 0.01, *P< 0.05, #P= 0.08 statistics based
on (A, C, E) Mann–Whitney U-test or (D, F) ANOVA/Fisher LSD test.
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compared with controls (Figure 4A-D,I; see Additional file
4: Figure S4). In addition to this overall increase in CD68
IR, there were widespread changes in both size and morph-
ology of microglia, specifically in the hippocampus, indicat-
ing the activated state [32] (Figure 4D). The microglial
changes in double immune-challenged mice were accom-
panied by a massive hippocampal astrogliosis (PP versus
NP; Figure 4E-H,J; see Additional file 5: Figure S5). Based
on these results, we suggest that prenatal immune chal-
lenge induces a subacute but persistent activation of micro-
glia [35], which is probably responsible for the rise in
inflammatory cytokines during adulthood, and may even
induce a slow but gradual deterioration of the brain’s innate
immune system during aging [36]. A second immune chal-
lenge that is accompanied by pronounced astrogliosis is
expected to accelerate this process, ultimately resulting in
dysregulation of brain metabolism and strongly affecting
neuronal health [37].
To test whether the pathological changes seen in glial
cells of double immune-challenged mice coincided with
an aggravation of AD-like neuropathology, we combined
immunohistochemistry and biochemistry to assess
Figure 2 Long-term changes induced by a prenatal infection include increased anti- amyloid precursor protein (APP)/Aβ
immunoreactivity (IR) and somatodendritic accumulation of pTau IR. Representative images of immunoperoxidase staining using (A,B)
anti-Aβ1–40/42 antibody and (D,E,G,H) anti-phosphorylated Tau205 taken from the dorsal hippocampus of 15-month-old non-transgenic mice prenatally
exposed to saline (NaCl) or polyriboinosinic-polyribocytidilic acid (PolyI:C). Quantitative analyses of the area covered by (C) anti-APP/Aβ IR or (F) anti-
pTau IR in hilar mossy cells. Values are given as mean ± SEM, n= 6 per treatment. *P< 0.05; statistical significance based on Mann–Whitney U test.
(D,E) Translocation of pTau IR from axonal to somatodendritic compartments in the dentate gyrus (DG) and hilus after prenatal infection. (G-H)
Representative higher-magnification image of the dorsal DG, showing the typical axonal pTau IR in the inner molecular layer of the DG (axonal
terminals of contralateral hilar mossy cells, upper arrow) and in the neuropil of the hilus (axonal collaterals of DG granule cells, lower arrow) in NaCI-
exposed control subjects. Compared with controls, a pronounced increase in pTau IR in somatic compartments was evident in the PolyI:C-treated
offspring, as indicated by the distinct labeling of DG granule cells and hilar mossy cells (red arrows). At the same time, IR in the axonal compartments
of the two cell types was strongly reduced. (I) Schematic overview of the observed changes within CA1 and DG between treatment groups,
emphasizing the change in subcellular distribution of pTau from axonal to somatodendritic compartments. The drawing on the left highlights the
dendritic arborization of a DG granule cell in the outer molecular layer, and indicates the axonal collaterals in the hilus. On the right, the projection of
the mossy cells to the inner molecular layer of the DG (commissural; that is, targeting the contralateral hemisphere) are shown. Abbreviations: a, axonal
projection area; d, dendritic subfield; gcl, granule cell layer; iml, inner molecular layer; oml, outer molecular layer; s, somatic subfield; slm, stratum
lacunosum moleculare. Scale bars: B = 500 μm, H=50 μm.
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amyloidogenic APP processing. Using optimized anti-Aβ
immunoperoxidase staining [26], we found a pronounced
amyloid-like plaque deposition in double immune-
challenged mice compared with controls (Figure 5A-G).
The pathology was most prominent in the anterior piri-
form and lateral entorhinal cortices and their axonal pro-
jection areas (Figure 5A-B; see Additional file 6: Figure
S6), which are among the first areas affected in AD [38].
In line with observations from human patients with AD
[39,40], some of the plaques were associated with the
cerebral vasculature (Figure 5I-K) and accompanied by
activated microglia (Figure 5F,I). To investigate the com-
position of these plaques, double-immunofluorescence
staining was performed using the N-terminal specific anti-
APP and anti-Aβ1–40/42 antibodies. This showed a pro-
nounced accumulation of APP and its fragments contain-
ing the N-terminal domain in the deposits (Figure 5H),
whereas Aβ/CTFs detected with anti-Aβ1–40/42 antibodies
were only enriched in cells closely associated with the
plaques (Figure 5H). Biochemical evaluations con-
firmed the significant increase in APP, sAPP, and AICD
levels after a second immune challenge (Figure 5L-M).
However, neither biochemistry nor immunohistochemis-
try investigations showed any evidence of a significant ac-
cumulation of mouse Aβ in these APP depositions, which
might be because of the different aggregation properties of
rodent compared with human Aβ peptides, or might be
linked to the premature age and disease stage of these
animals.
To test whether inflammation-induced accumulation
of APP and its fragments may represent a seeding point
for senile, human-like Aβ deposits, we used transgenic
mice (3xTg-AD), an established mouse model of AD
[23], and challenged them with PolyI:C at the pre-plaque
stage of 4 months [23]. Immunohistochemical analysis at
15 months showed a dramatic increase in Aβ plaque depos-
ition in the entire hippocampus of PolyI:C-treated com-
pared with saline-treated mice (Figure 6A-B; see Additional
file 7: Figures S7 and Additional file 8: Figure S8).
Except for the large subicular plaques, most of the
deposits were thioflavinS-negative, indicating that the
inflammation-induced plaques were not fibrillary in
Figure 3 Age-associated impairments in performance in polyriboinosinic-polyribocytidilic acid (PolyI:C) mice in the Y-maze test.
(A-B) ANOVA of the % alternation showed a significant main effect for treatment (F1,54= 90.1, P< 0.001) and age (F1,54= 39.8, P< 0.001), and a
treatment × age interaction (F3,54= 70.6, P< 0.001), but no effect for sex (F1,54= 0.0002, P= 0.988). Fisher's LSD post-hoc analysis confirmed the
significant impairment in working-memory performance in the 20 month-old PolyI:C-exposed subjects compared with NaCI-treated subjects in
(females: P< 0.001, males: P= 0.003). (C-D) ANOVA of the total distance travelled identified a significant main effect for age (F1,54 = 10.0, P= 0.003)
and sex (F1,54 = 16.5, P< 0.001), but no main effect for treatment (F1,54= 0.51, P= 0.480), indicating that the memory impairment was not
confounded by differences in locomotor activity. Post-hoc analysis indicated that males travelled significantly shorter distances than did females
(P= 0.0003, Fisher's LSD Post-hoc analysis). (E-F) Similarly, ANOVA of the total number of entries into the Y-maze arms showed no significant main
effect for treatment (F1,54= 0.53, P= 0.470), but a main effect for sex (F1,54 = 11.1, P= 0.002), reflecting the lower activity of males relative to females
(P= 0.002, Fisher's LSD post-hoc analysis). Besides the effect for age, which closely approached significance (F1,54 = 3.8, P= 0.056), a significant
age × sex interaction emerged (F3,54=4.2, P= 0.045), indicating the lower activity of old males relative to females. Values are given as mean± SEM;
n = 13 to 18 per age and treatment; ***P < 0.001, **P < 0.01.
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nature (Figure 6C-H). However, most of these plaques
contained Fluoro-Jade-positive cores (Figure 7A-C) and
were surrounded by activated caspase 6-positive (Figure
7D-F) and silver-positive dystrophic neurites (Figure 6I-K),
indicating degenerative processes accompanying amyloid
deposition in immune-challenged 3xTg-AD mice. Import-
antly, inflammation-induced plaques contained significant
amounts of proteolytic APP fragments (Figure 7D,G), as
seen in double immune-challenged WT mice (Figure 5H),
and were surrounded by Aβ peptides (Figure 7G-I) that
Figure 4 Microglia activation accompanied by prominent astrogliosis in double immune-challenged non-transgenic mice.
Immunoperoxidase staining of brain sections from 18-month-old NP (NaCl at gestation day (GD)17, PolyI:C at 15 months) and PP
(polyriboinosinic-polyribocytidilic acid (PolyI:C) at GD17, PolyI:C at 15 months) mice. Increase in (A-D) CD68 and (E-H) glial fibrillary acidic protein
(GFAP) immunoreactivity (IR) in the PP hippocampus. (D) Note the strong hypertrophy of CD68-positive microglia in PP versus NP subjects,
indicative of their activated state. Quantitative analysis of hippocampal (I) anti-CD68 and (J) GFAP IR representing total area and mean size of
activated microglia and astrocytes, respectively. Values are given as mean ± SEM, n = 5 per treatment. *P< 0.05; statistical significance based on
Mann–Whitney U test. Scale bars: (A,E) = 500 μm; (C) = 20 μm, (G) = 50 μm.
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had a striking similarity to the morphology of senile Aβ pla-
ques seen in human patients with AD (Figure 7J-L; see Add-
itional file 9: Figure S9). These results suggest that the
inflammation-induced APP depositions represent a seed for
amyloid plaques in both rodents and humans.
Apart from the amyloid pathology, we also investi-
gated the effect of a second immune challenge on Tau
pathology. In double immune-challenged WT mice (PP),
immunohistochemical staining showed a significant in-
crease in pTau IR in all subfields of the hippocampus
Figure 5 (See legend on next page.)
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(Figure 8A-C), accompanied by widespread mis-sorting
and aggregation of phosphorylated Tau in neuronal
somata, compared with control mice (Figure 8D-F). We
also detected a significant increase in the level of PHF-
Tau, whereas soluble pTauT205 levels were significantly
reduced (Figure 8G-H), indicating abnormal aggregation
of pTau after the double immune challenge. However,
we did not observe neurofibrillary tangles (NFTs) in PP
mice. Analysis of the Tau phosphorylation levels in
immune-challenged 3xTg-AD mice showed that, apart
from a strongly increased pTau IR level in the hippocam-
pal formation (Figure 8I-J; see Additional file 8:
Figures S8 and Additional file 10: Figure S10), a single
PolyI:C injection during pre-plaque stage was sufficient to
induce tangle-like structures in neuronal somata outside
the high tau transgene expression sites, including the
somatosensory cortex (Figure 8I-J, inset). It is conceivable,
therefore, that sustained activation of microglia, Aβ accu-
mulation, and/or chronic neuroinflammation is required
to induce the development of NFTs in non-transgenic
mice [41].
Taken together, the results presented here demonstrate
that systemic immune challenges not only represent a
crucial trigger but also a potent driver of AD-like neuro-
pathology in both environmentally (PolyI:C exposure at
GD17) and genetically (3xTg-AD) predisposed animals,
in agreement with the notion that peripheral infections
and inflammation in patients with AD are associated
with more rapid cognitive decline and exacerbation of
their symptoms [42].
Discussion
In this study, we provide the first evidence that a systemic
immune challenge during a late-gestational time window
(GD17) predisposes WT mouse offspring to pathological
brain aging and cognitive decline. A second immune chal-
lenge aggravates this phenotype and is sufficient to pre-
cipitate significant and widespread amyloid-associated and
pTau-associated neuropathology in the aged offspring. By
administering a single systemic infection to genetically
predisposed transgenic mice (3xTg-AD) overexpressing
the human variants of AD-relevant genes [23], we con-
firmed that the AD-like neuropathological hallmarks seen
in double immune-challenged WT mice represent an early
AD precursor stage, which is also seen in human patients
with AD. Thus, the PolyI:C model offers a unique oppor-
tunity to identify molecular targets that are strongly
affected by chronic inflammatory conditions and involved
in the initiation of the typical neuropathology characteris-
tic of sporadic AD.
Our experimental design builds on our previous stud-
ies, in which we showed that middle (GD9) and late
(GD17) gestational periods correspond to two windows
of enhanced vulnerability to inflammatory cytokines
[19]. Whereas mid-gestational immune challenges re-
sulted in neurochemical and behavioral impairments
that were releveant for schizophrenia [20], late-gestational
PolyI:C exposure has a detrimental and long-term effect
on cognitive performance during adulthood and aging
[19], suggesting a causal link between disturbances of late
embryonic development and risk of AD-like neuropathol-
ogy [22].
In this study, we extended our previous findings that
PolyI:C injection at GD17 induced a significant elevation
of maternal and fetal cytokines at both protein and
mRNA levels [19], by showing that this insult also has
long-term consequences on basal cytokine levels in
adulthood. We detected significantly increased levels of
both circulating and brain IL-1β in PolyI:C-treated versus
saline-treated mice throughout aging. It is conceivable that
these changes are linked to the detrimental effect of the
prenatal immune challenge on the developing microglia,
the macrophage-derived immune cells of the brain that
start to colonize the brain during late-gestational stages
[43,44], potentially affecting their proliferative and also pha-
gocytotic capacity during adulthood and aging. In addition,
(See figure on previous page.)
Figure 5 An adult immune challenge induces amyloid precursor protein (APP) accumulation in non-transgenic mice prenatally
exposed to polyriboinosinic-polyribocytidilic acid (PolyI:C). (A,B) Coronal brain sections of 15-month-old single (NP, NaCl at gestation day
(GD)17, PolyI:C at 12 months) and double (PP, PolyI:C at both GD17 and 12 months) immune-challenged mice processed for anti-Aβ1–16
immunoperoxidase staining. Images are color-coded for visual display. (C) Enlarged view (box in B) of a representative precursor plaque.
(D) Quantitative analysis of the numerical plaques density in all four treatment groups. Values are given as mean± SEM, n = 6 to 7 per treatment.
*P< 0.05, **P< 0.01; statistical significance based on ANOVA and Fisher LSD post-hoc analysis. (E-F) Confocal images captured in the entorhinal
cortex of NP and PP brain sections processed for triple immunofluorescence staining. Activated microglia (CD68, green) were found in close
vicinity to the plaques (anti-Aβ1–16) in PP mice. (G) Enlarged neuron in the entorhinal cortex (arrow in F) counterstained with DAPI (blue)
displaying intracellular anti-Aβ1–16 IR (red). Bottom image shows confocal view along the xz axis. (H) Anti-N-terminal APP antibody (green)
revealed strong accumulation of APP ectodomains in extracellular deposits located in the entorhinal cortex (PP mouse), whereas anti-Aβ1–40/42
(red) IR was seen only in surrounding neurons. (I-K) Pronounced accumulations of APP deposits (anti-Aβ1–16, red) in the cerebral vasculature in PP
mice were associated with microglia (anti-CD68 antibody, green). Blue channel shows the DAPI nuclear counterstaining. (L) Western blots of
hippocampal lysates obtained from 12-month-old NP and PP mice using anti-N-terminal and anti-C-terminal APP antibodies. (M) Quantitative
analysis of the immunoreactive signals. Values represent mean relative optical density normalized to β-Actin and expressed in arbitrary units (AU)
(mean± SEM, n = 6 to 7). ***P< 0.001, **P< 0.01, *P< 0.05, #P= 0.08; statistics is based on Mann–Whitney U test. Scale bars: (B) = 500 μm,
(C,F,I) = 20 μm, (G) = 5 μm, (H) = 10 μm.
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the immune challenge may prime or activate microglia,
thereby creating an innate immune memory, allowing a fas-
ter and exaggerated response upon further immune chal-
lenges and exposures to adverse stimuli [35]. Indeed, in
double immune-challenged mice we found a pronounced
increase in activated microglia in the hippocampus before
the accumulation of extracellular amyloid depositions. Fur-
thermore, chronic elevation of several cytokines after a late-
gestational immune challenge may also have a detrimental
effect not only on neurons but also on microglia, by pro-
moting cytokine-mediated release of reactive oxygen spe-
cies [45]. In combination with additional immune
challenges in adulthood, these pathophysiological changes
may detoriate, resulting in loss of the neuroprotective
functions of microglia and even microglial degeneration,
which in turn may contribute to the spread of neuro-
pathology in AD. Experimental evidence for this hy-
pothesis is provided by in vitro findings showing that
repetitive stimulation of microglia by mitogens induces
telomere shortening and replicative senescence [46],
and that interferon-γ exposure is sufficient to trigger
activation-induced microglia cell death [47]. Hence, fur-
ther morphological and biochemical investigations will
be required to determine whether microglia in the aged
immune-challenged WT mice may also share character-
istics of fragmentation and degeneration, a distinct neu-
ropathologic feature preceding the spread of tau and
neuritic plaque pathology in patients with AD [48].
In this study, we also found that chronic rises in in-
flammatory cytokines are accompanied by significant
rises in APP and its proteolytic fragments, and an in-
crease in Tau phosphorylation and somatodendritic mis-
localization in aged animals. These observations are in
agreement with data showing that ectopic IL-1 applica-
tion increases APP production and its processing
[10,49,50], and increases Tau hyperphosphorylation [51].
In addition, we found that an increase in C-terminal
APP fragments, including AICD, which potentially con-
tributes to the neuroinflammation response [33], was
one of the first significant changes discovered in the
course of aging of prenatally challenged animals. It is
also plausible, however, that an early life insult may re-
sult in long-lasting epigenetic changes in the promoter
region of AD risk genes, as previously proposed [52],
providing an alternative explanation for the chronic inflam-
matory state occurring after prenatal immune challenge.
Based on recent findings showing that systemic in-
flammation exacerbates the course of the disease both in
patients with AD [42] and in rodent models of the dis-
ease [53], we tested the effect of the second immune
challenge in adulthood on AD-relevant neuropathology.
Analysis of these double immune-challenged mice
showed a strong aggravation of the phenotype that was
present after a single prenatal infection. Moreover, we
detected the appearance of extracellular APP/Aβ-positive
deposits in the entorhinal and piriform cortex and the
formation of intracellular Tau aggregates, selectively in
the hippocampal formation. Hence, dysfunction of the
brain’s immune system, triggered through systemic infec-
tions, may play a key role in initiation of AD pathogen-
esis, in line with previously proposed hypotheses [37,54].
The existence of APP/Aβ-positive deposits in double
immune-challenged non-transgenic mice, in brain areas
which are among the first affected in humans [38] indi-
cated that better characterization of these amyloid-like
plaques is needed. Using N-terminal specific anti-APP
and anti-Aβ1–40/42 antibodies, we showed that, whereas
the deposits consisted of APP and N-terminus-
containing APP fragments, Aβ/CTFs were enriched only
in cells closely associated with plaques. The absence of
significant accumulations of mouse Aβ peptides in these
APP deposits might be due to the different aggregation
properties of the rodent compared with the human form
[55], or might be linked to the premature age and dis-
ease stage in these animals (15 months). It will therefore
be important to determine the precise identity of the dif-
ferent APP fragments produced in aged single and
double immune-challenged mice.
In the current study, we tested the possibility that the
inflammation-induced accumulation of APP and its pro-
teolytic fragments may represent a seeding point for fi-
brillary Aβ deposits. For that we used the 3xTg-AD mice
(See figure on previous page.)
Figure 6 Single immune challenge in adults induces a dramatic increase in Aβ plaque burden and prominent neurodegeneration in
3xTg-AD mice. Representative images of (A-B) immunoperoxidase labeling, (C-H) immunofluorescence, and (I-K) silver staining of coronal brain
sections of 15-month-old 3xTg-AD mice (Tg) exposed to polyriboinosinic-polyribocytidilic acid (PolyI:C) or NaCI (NaCl) at 4 months of age.
(A-B) The typical anti-Aβ1–16 IR seen in the NaCI-treated mice was significantly aggravated after PolyI:C exposure. (C-D) Counterstaining revealed
newly formed Aβ plaques in subiculum and CA1 (arrows) that were thioflavinS (ThioS)-negative, suggesting the non-fibrillary nature of the
immune challenge-induced plaques. (E-H) Representative images of the ventral CA1 area of (E, F) NaCI-treated and (G,H) PolyI:C-treated
transgenic animals, highlighting the striking increase in ThioS-negative Aβ plaques after a single immune challenge. (I-K) The increased plaque
deposition in PolyI:C-treated 3xTg-AD mice was accompanied by distinct neurodegeneration. Note the dark precipitates in the vicinity of large
plaques in PolyI:C treated mice. (J,K) Higher-magnification color image acquired in the marked area in (J) showing the dense silver precipitates,
indicative of dystrophic neurites (red arrows), surrounding Aβ plaques (gray/yellow). Abbreviations: so, stratum oriens; sr, stratum radiatum; slm,
stratum lacunosum moleculare; Sub, subiculum; DG, dentate gyrus. (A) = 500 μm; (C) = 150 μm; (E; K) = 50 μm; (I) = 100 μm.
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Figure 7 (See legend on next page.)
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(See figure on previous page.)
Figure 7 Characterization of the inflammation-induced Aβ plaques in 3xTg-AD mice. (A-C) Immunofluorescence staining using anti-Aβ1–16
antibody (red) counterstained with Fluoro-Jade (green) and DAPI (blue) revealed, in addition to the dystrophic neurites (arrows), the presence of
degenerating neurons in the core of amyloid deposits in immune-challenged transgenic mice. (D-F) Double-immunofluorescence staining using
anti-N-APP (red) and anti-activated caspase-6 (green) confirmed the presence of dystrophic neurites within and around the amyloid deposits.
(G-I) Transgene-driven human Aβ aggregates (green, anti-Aβ1–40/42) around the APP/soluble (s)APP (red, anti-N-APP) accumulations in PolyI:C-
treated 3xTg-AD mice, in striking similarity to the phenotype seen in human patients with AD (J-L). Note the close association but no
colocalization between APP ectodomains and C-terminal, Aβ-containing fragments (G-L). Scale bars = 10 μm.
Figure 8 (See legend on next page.)
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[23] and challenged them with PolyI:C at the pre-plaque
stage. Subsequent analysis at 15 months showed a dra-
matic increase in Aβ plaque deposition in the entire
hippocampus of the PolyI:C-treated mice. These data are
in line with recent findings of accelerated Aβ pathology
in transgenic AD mice after induction of osteoarthritis,
which is accompanied by significant upregulation of
inflammation-related genes and astrocyte and microglial
activation in the brain [56]. Importantly, inflammation-
induced plaques contained significant amounts of pro-
teolytic APP fragments, as seen in double immune-
challenged WT mice (Figure 9A-D). These APP-derived
aggregates were surrounded by human Aβ peptides,
showing a striking similarity to the morphology of Aβ
plaques seen in human patients with AD (Figure 9E-F).
Importantly, other laboratories have also reported ro-
dent APP in the core of Aβ deposits in variuos trans-
genic AD mouse strains [55,57]. Hence, we conclude
that accumulation of APP and its N-terminus-containing
fragments precedes the formation of senile plaques, repre-
senting a crucial and conserved precursor stage of this
typical neuropathologic hallmark.
In agreement with recent experimental evidence show-
ing that hyperphosphorylated, non-fibrillary Tau may have
a key role in eliciting behavioral impairments in vivo
[34,58], we were able to show in this study that the Tau
hyperphosphorylation and mislocalization into somato-
dendritic compartments is accompanied by severe deficit
in prenatally challenged mice compared with saline-
treated controls. However, it would be interesting to con-
firm if a second immune challenge during aging results in
progressive decline of cognitive functions, as indicated by
the recent findings in patients with AD, providing evi-
dence that acute and chronic systemic inflammation is
associated with an increase in cognitive decline [42]. Al-
though we did not observe the formation of NFTs in
immune-challenged mice, a second immune challenge in
our model elicited the intraneuronal aggregation of Tau,
probably involving the formation of PHFs. Further studies
will be required to characterize the nature of these and
potentially other phosphorylated epitopes affected by the
chronic inflammatory state. We have recently shown that
NFT-like structures can form in the brain of AD mice
lacking tau transgene expression, by genetic reduction of
the reelin gene [27]. Interestingly, formation of these
NFT-like structures was associated with a high Aβ plaque
burden, and prominent neuroinflammation and neurode-
generation [27]. Hence, it is reasonable to suggest that the
formation of PHFs we saw in double immune-challenged
WT mice would eventually develop into NFTs at older
age and later stages of the disease.
In summary, and based on the results presented and
discussed here, we propose a model (Figure 9G) in
which the mendelian mutations underlying familial AD
cause profound changes in APP metabolism, inducing a
neuroinflammatory response capable of driving and ag-
gravating AD neuropathology during aging. Repeated
systemic immune challenges, by contrast, induce
chronic neuroinflammation and may accelerate senes-
cence of microglia cells. Reduction in their neuropro-
tective function is expected to impair both APP and
pTau homeostasis. This in turn could trigger a vicious
cycle that will lead, over the course of aging, to the for-
mation of senile Aβ plaques and NFTs, induce degener-
ation, and ultimately result in clinical dementia. We
suggest, therefore, that systemic infections and persist-
ent neuroinflammatory conditions represent major risk
factors for the development of sporadic AD in older
persons. Importantly, our model complements the
long-standing amyloid hypothesis of AD [59,60], and is
in accordance with the recent proposal to revise the
current view on the etiology of sporadic AD [61].
(See figure on previous page.)
Figure 8 Aggravated Tau pathology after systemic infection in adult mice. Representative images of coronal brain sections obtained from
(A,D) NP (NaCl at gestation day (GD)17, PolyI:C at 12 months) and (B,E,F) PP mice (PolyI:C at GD17 and at 12 months), processed for (A,B)
immunoperoxidase and (D-F) immunofluorescence staining using anti-phosphorylated TauT205 antibodies. (A,B) Images are color-coded for visual
display, with white/yellow indicating highest and blue/purple lowest staining intensity. (C) Quantitative analysis of the optical density (OD) of
pTau IR in the hippocampus of all treatment groups. Values represent mean OD values corrected for non-specific background labeling
(mean± SEM), n = 6 to 7. **P< 0.01, *P< 0.05; statistical significance based on ANOVA/Fisher’s LSD post-hoc analysis. (D-F) Increase in pTau IR in
CA1 is accompanied by mis-sorting into dendrites and intraneuronal aggregation in non-transgenic PP mice. (F) Enlarged view of the CA1
stratum lacunosum moleculare subfield showing the typical somatic pTau aggregation. (G) Biochemical analysis of Tau phosphorylation using
anti-paired helical filaments (PHFs), anti-pTauT205, and anti-total Tau antibodies. Lanes represent individual mice. (H) Quantitative analysis of the
immunoreactive signals. Values represent mean relative optical density normalized to β-Actin and expressed in arbitrary units (AU) (mean± SEM,
n = 6 to 7). **P< 0.01; Mann–Whitney U test. Please note that the pTauT205antibody was used for (A,B) immunohistochemistry (IHC) and (G)
immunoblotting (IB) experiments. Because this antibody can crossreact with Ser199 in mouse Tau, an epitope that can be detected with the
AT100 (PHF) antibody [63], the increase of pTau IR in (A,B) is potentially due to an increase in aggregated pTau in sections. (I-J) Anti-pTauT205 IR
in the ventral hippocampus of 15-month-old 3xTg-AD mice injected with NaCI or PolyI:C at 4 months. Insets show higher magnifications of the
cortical areas (asterisk) with low transgene expression, and indicate formation of distinct neurofibrillary tangle-like structures after a single
systemic infection in transgenic AD mice. Scale bars: (A) = 500 μm, (D) = 30 μm, (F) = 5 μm, (I, inset) = 50 μm, (J) = 500 μm.
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Figure 9 Inflammation-induced amyloid precursor protein (APP) accumulations represent an early neuropathologic feature in the
pathogenesis of Alzheimer’s disease (AD). Extracellular APP or soluble (s)APP-containing amyloid plaques in rodents and humans share striking
morphological similarities. Tissue sections obtained from (A-B) 15-month-old double immune-challenged (polyriboinosinic-polyribocytidilic acid
(PolyI:C) at GD17, PolyI:C at 12 months) wild-type (WT) mice, (C-D) 1-month-old 3xTg-AD mice exposed to PolyI:C at 4 months, and (E-F) an
88-year-old patient with AD. Images were acquired with the same confocal settings in representative areas within the hippocampal formation:
layer III-IV in the lateral entorhinal cortex (ECtx, PP), CA1 stratum radiatum (sr, 3xTg-AD mice), and CA1 stratum pyramidale (sp, human subject).
Antibody used: anti-N-APP (red) and anti-Aβ1–40/42 (green). (G) Model proposing an AD mutation-independent role of systemic immune
challenges, persistent neuroinflammation, and deterioration of innate immunity in the etiology of the age-associated, sporadic form of AD. Scale
bars: (A-E) = 10 μm; (F) = 20 μm.
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Conclusion
We provide experimental evidence for a causative and
exacerbating role of systemic immune challenges on the
development of AD-like neuropathology in vivo, thereby
supporting recent genome-wide association studies [4],
retrospective epidemiological human studies [5,6,12], and
the long-standing infection/neuroinflammation-based AD
hypotheses [11,22,33,61]. Furthermore, our data support
the use of anti-inflammatory drugs [12] in the treatment
of patients during the initial asymptomatic stages of AD
[16], and confirm the importance of identifying early mo-
lecular markers of the disease. Finally, with the novel find-
ings of focal accumulations of APP and its proteolytic
fragments preceding senile plaque deposition, we offer a
very suitable mouse model to elucidate the molecular
mechanisms underlying the earliest stages of the typical
neuropathologic changes characteristic of sporadic AD.
Additional files
Additional file 1: Figure 1. Chronic increase in proinflammatory
cytokines following a prenatal immune challenge in the hippocampus
but not neocortex. (A-C) ELISA of neocortical (Ctx) and hippocampal
(Hip) brain lysates obtained from 15-month-old polyriboinosinic-
polyribocytidilic acid (PolyI:C)-treated and NaCI-treated mice (n = 4–7 per
treatment group). Values represent mean ± SEM. *P< 0.05, Mann–Whitney
U-test. (D-K) Immunohistochemical staining using anti-CD68 antibodies
to visualize microglia in the hippocampus. Representative images are
taken at different magnification from the dorsal CA1 of 15-month-old
mice treated with (D,F,H) NaCI and (E,G,I) PolyI:C. Higher-magnification
images show the activated stage (arrow) in microglia in the CA1 stratum
lacunosum moleculare (slm) in 15-month-old mice (H) treated with
PolyI:C compared with (I) control mice. (J,K) Anti-CD68 immunoreactivity
(IR) in young (8 weeks) and old (15 months) naive wild-type (WT) mice.
Whereas very small somata and thin processes dominated in young mice
(J), microglia in old naive mice covered larger areas (K), very similar to
the situation in old NaCI-exposed mice. Scale bars: (D) = 500 μm;
(F) = 100 μm; (H, J) = 20 μm.
Additional file 2: Figure 2. Changes in amyloid precursor protein (APP)
processing and Tau phosphorylation across aging after a single prenatal
immune challenge in non-transgenic mice. Longitudinal study involving
murine hippocampal brain lysates obtained from (A,D) 3-month-old,
(B,E) 6-month-old, and (C,F) 2-month-old non-transgenic mice exposed
in utero at gestation day (GD)17 to either polyriboinosinic-polyribocytidilic
acid (PolyI:C) or NaCI. The latter cohort also received a single NaCI
injection at 9 months, and constituted the control group for the double
immune-challenged mice. Western blots were performed using the
following antibodies: (A-C) mouse anti-APP A4 (clone 22 C11, recognizing
full-length APP, and soluble α- or β-secretase-cleaved APP ectodomains
(sAPP); rabbit anti-C-terminal APP (A8717, recognizing α- or β-secretase-
generated C-terminal fragments (CTFs) and γ-secretase-cleaved APP
intracellular domains (AICD)); and mouse anti-β-Actin (clone 4).
(D-F) Western blots using mouse anti-paired helical filaments (PHFs,
clone AT100), rabbit anti-phosphorylated Tau205, and mouse anti-total
Tau (Tau-5) antibodies. Quantitative analysis involved the measurement
of the integrated pixel brightness of the immunoreactive bands,
corrected for non-specific background and equal loading using β-actin as
control. Please note that the pTau blot in E has been overexposed for
visual display. Western blot lanes show the different subjects. Values
represent mean relative, β-actin-corrected optical density expressed in
arbitrary units (AU) (mean ± SEM, n = 4 to 6 per treatment and age).
*P< 0.05, **P< 0.01, # P= 0.053, Mann–Whitney U-test.
Additional file 3: Figure 3. (A) Schematic representation of the domain
structure of the amyloid precursor protein (short form, APP695), indicating
α-, β- and γ-secretase cleavage sites and antibody binding sites. Note
that antibody Aβ1–16 (6E10) recognizes both Aβ/C-terminal fragments
(CTFs) as well as full-length APP on western blots and tissue sections (see
Figure 5). By contrast, antibody Aβ1–40/42 has very low affinity for full-
length APP but strongly binds to Aβ/CTF fragments.
(B) Schematic representation of the human Tau protein (441 amino acid,
longest isoform). Alternative splicing of mRNA from a single gene located
on the long arm of chromosome 17 yields six different isoforms that are
expressed in the adult human brain [62]. They differ by the presence of
one to two amino-terminal inserts (blue) and three to four tandem
repeats (purple) in the carboxyterminal region. The sequence common to
all known isoforms is shown in gray. The phosphorylation-dependent
anti-Tau antibodies used are listed (including their alternative names)
along with the respective phosphorylation-site and flanking sequences.
As can be seen from the alignment of the tau sequences in five species,
there is a high level of homology between mouse and human tau. Note
that pTauT205 antibody also crossreacts with Ser199 in mouse Tau, an
epitope that can also be detected with the AT100 (PHF) antibody [63]
Abbreviations:CTF, C-terminal fragment; AICD, APP intracellular domain;
PM, plasma membrane; sAPPα/β,soluble α- or β-secretase-cleaved.
Additional file 4: Figure 4. Microglia responses in double immune-
challenged non-transgenic mice. (A-D) Low-magnification images of
immunoperoxidase staining using anti-CD68 antibody (MCA 341R) of
coronal brain sections obtained from 18-month-old control mice (NN;
NaCI at gestational day (GD) and 15 months), and prenatal (PN;
polyriboinosinic-polyribocytidilic acid (PolyI:C) at GD17 and NaCI at
15 months), adult (NP; NaCI at GD17 and PolyI:C at 15 months), and
double (PP, PolyI:C at GD17 and 15 months) immune-challenged
mice. (D) A pronounced increase in the density of activated CD68-
positive microglia with hypertrophied and ameboid morphology was
found throughout the hippocampal formation of double immune-
challenged mice compared with control subjects. Note that also
immune challenge (B) prenatally and (C) in adulthood alone had a
stimulating effect on microglia OD. (E-F) Quantitative analysis of the
immunoreactive signals labeled with antibodies against rat CD68. (E)
ANOVA yielded a main effect of treatment for the quantification of
percentage area covered by anti-CD68 immunoreactivity (IR) in the
hippocampus (F3,16 = 4.4, P = 0.019) with significant differences
between NN versus PP (P= 0.004), NP versus PP (P = 0.015), and PN
versus PP (P= 0.026). (F) A significant main effect also emerged for
the mean area (F3,16 = 3.2, P= 0.049) with significantly higher levels of
hypertrophied microglia in NN versus PP (P = 0.007). Values represent
mean ± SEM (background corrected, n = 4 to 6 per treatment).
*P< 0.05, **P< 0.01; Fisher's least significant difference post-hoc
analysis. Scale bar = 200 μm.
Additional file 5: Figure 5. Reactive astrogliosis following a double
immune challenge in aged non-transgenic mice. (A-D) Low-
magnification images of immunoperoxidase staining using rabbit
anti-glial fibrillary acidic protein (GFAP) antibody (AB5804) of coronal
brain sections obtained from 18-month-old control mice (NN; NaCI at
gestational day (GD) and 15 months), and prenatal (PN;
polyriboinosinic-polyribocytidilic acid (PolyI:C) at GD17 and NaCI at
15 months), adult (NP; NaCI at GD17 and NaCI at 15 months), and
double (PP, PolyI:C at GD17 and 15 months) immune-challenged
mice. (D) A pronounced increase in the density of GFAP-positive
astrocytes was evident in the hippocampal formation of double
immune-challenged mice compared with control subjects. Note that
also an immune challenge (B) prenatally and (C) in adulthood alone
showed a trend towards elevated/reactive astrogliosis. (E) ANOVA
yielded a main effect of treatment for the quantification of
percentage area covered by anti-GFAP immunoreactivity (IR) in the
hippocampus (F3,16 = 3.4, P= 0.040) with significant differences
between NN versus PP (P= 0.011) and NP versus PP (P = 0.021).
(F) Volumetric analysis of the hippocampus revealed no significant
differences between the treatment groups at this age. Values are
given as mean ± SEM, n = 4 to 6 per treatment; *P< 0.05; statistical
significance based on Fisher’s least significant difference post-hoc
analysis. Scale bar = 500 μm.
Additional file 6: Figure 6. Grayscale version of the low-
magnification images shown in Figure 5 (anti-Aβ1–16) and Figure 8
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(anti-pTauT205). (A,D) Digital images obtained from NP (NaCI at GD17 and
polyriboinosinic-polyribocytidilic acid (PolyI:C) at 12 months) mice. (B,C,E)
Low-magnification and high-magnification images of brain sections taken
from PP mice (PolyI:C at GD17 and 12 months). Image in panel
(C corresponds to the boxed area in (B). Scale bars (B,E)= 500 μm,
(C)= 200 μm.
Additional file 7: Figure 7. Aβ immunoreactivity (IR) in the dorsal and
ventral hippocampus of 15-month-old mice. Representative images of
coronal brain sections processed for immunoperoxidase staining using
anti-Aβ1–40/42 (AB5076) antibodies. (A-D) Non-transgenic mice and (E-H)
3xTg-AD mice, harboring two transgenes (encoding APPswe and
TauP301L, respectively) in a homozygous PS1M146V knock-in
background,received a single intravenous injection of (left lane) NaCI or
(right lane) PolyI:C (5 mg/kg bodyweight) at 4 months of age. Note that
the non-transgenic mice showed an increase in anti-APP/Aβ1–40/42 IR
along the dorsal-ventral axis of the hippocampus following a single viral-
like infection with (B,D) PolyI:C compared with (A,C) NaCI. (E,G) Control
treatment of 3xTg-AD mice with NaCI during pre-plaque stage resulted
in the typical appearance of Aβ plaques in the ventral subiculum,
whereas (F,H) a single exposure to PolyI:C strongly aggravated the Aβ
plaque density, covering the entire hippocampus along its septotemporal
axis. Scale bars: 500 μm.
Additional file 8: Figure 8. Summary of the semi-quantitative
densitometric analysis of the anti-Aβ and anti-Tau immunoreactivity (IR).
Polyriboinosinic-polyribocytidilic acid (PolyI:C; 5 mg/kg body weight) or
NaCI in a injection volume of 5 ml/kg was administered intravenously to
mice at 4 months of age. Brain tissue was collected at 15 months, and
processed for immunoperoxidase staining. Optical-density measurements
were performed in the outlined CA1 subfield (including stratum oriens,
pyramidale, radiatum), lacunosum moleculare (slm), the molecular and
granule cell layer of the dentate gyrus (DG), and the hilus, both in the
dorsal and ventral hippocampus. Mean pixel brightness was corrected for
non-specific background staining using measurements in the corpus
callosum as reference, indicated as relative optical density (OD).
(A) Summary of the changes in APP/Aβ1–40/42 (left) and pTau (right)
levels in PolyI:C-treated compared with NaCI-treated 3xTg-AD mice.
Arrows show the direction of changes in the different hippocampal
subfields. Brackets indicate statistical trends, with P values of 0.06 to 0.09.
(B) Summary of the APP/Aβ and pTau measurements in non-transgenic
mice, contrasting PolyI:C-treated versus NaCI-treated mice. (C) Graphic
representation of the semi-quantitative analysis of (left) the APP/Aβ1–40/42
and (right) pTau immunoreactivity (IR) in the dorsal and ventral
hippocampus of non-transgenic and transgenic mice. Values are given as
mean± SEM; n = 4 to 7 per genotype and treatment; *P< 0.05; **P< 0.01,
ANOVA and Fisher's least significant difference post-hoc test.
Additional file 9: Figure 9. Various forms of human amyloid-β plaques
all containing significant amounts of N-terminal proteolytic fragments of
amyloid precursor protein (APP). (A-I) Immunofluorescence staining using
anti-N-APP antibodies (22C11, red), anti-Aβ1–40/42 (AB5076, green), and
DAPI (blue) counterstaining of post-mortem brain tissue from an 88-year-
old patient with AD. Paraffin sections were pretreated with (A-F) or
without (G-I) formic acid (FA), with the latter allowing the detection of
significant N-APP-specific immunoreactivity. Note the close association,
but no colocalization, between APP ectodomains and C-terminal, Aβ-
containing fragments. Scale bars = 10 μm.
Additional file 10: Figure 10. Anti-phospho-Tau IR in the dorsal and
ventral hippocampus of 15-month-old mice. Representative images of
coronal brain sections obtained from (A-D) non-transgenic and (E-H)
3xTg-AD mice challenged with a single viral-like infection with
polyriboinosinic-polyribocytidilic acid (PolyI:C) or NaCI at 4 months of
age, processed for immunoperoxidase staining using anti-pTauT205
antibodies (Ab4841) (A-D) Even non-transgenic mice showed an increase
in pTau IR following PolyI:C compared with NaCI injection, which was
particularly prominent in interneurons in CA1 and hilar mossy cells.
Asterisks indicate the position of neurons (enlarged in the inset box) with
distinct somatic pTau IR. (E,G) 3xTg-AD mice exposed to a single
intravenous NaCI infusion showed the typical phosphorylation pattern in
(E) dorsal and (G) ventral CA1 pyramidal neurons. (F,H) A single PolyI:C v
injection resulted in a significant increase in anti-pTau IR in the
somatodendritic compartments compared with control treatment.
(G’-H’) Higher magnification of the boxed area in (G) and (H),
respectively, showing CA1 pyramidal neurons. Scale bar: (A-G) = 500 μm;
(G’) = 50 μm.
Abbreviations
BSA: Bovine serum albumin; DAPI: 4',6-diamidino-2-phenylindole;
PBS: Phosphate-buffered saline.
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